Safety Notices

From time to time notices relating to the safety, efficacy and quality of human medicinal products are published by the Health Products Regulatory Authority.

The issues covered by these notices include medicinal product safety information, updated efficacy information on the appropriate usage of medicines and quality defect information.

Notices are categorised in accordance with their importance at time of publication.

The four notice categories are outlined as follows:

  • Advisory  -  Routine safety information            
  • Warning  -  Urgent safety information
  • Recall  -  Urgent safety information relating to a product recall
  • Publications  -  General information provided by 3rd parties as approved by the HPRA, e.g. MIMS, Direct Healthcare Professional Letter or Product Information Update

The HPRA Drug Safety Newsletter is also published on a regular basis.

Date Title Type
20/03/2020 HPRA MIMS Articles March 2020 3rd Party Publications
20/03/2020 HPRA MIMS Articles February 2020 3rd Party Publications
18/03/2020 Medicinal Product Shortages - update - 18 March 2020 Advisory
11/03/2020 Medicinal Product Shortages - update - 11 March 2020 Advisory
04/03/2020 Medicinal Product Shortages - update - 4 March 2020 Advisory
26/02/2020 Medicinal Product Shortages - update - 26 February 2020 Advisory
19/02/2020 Medicinal Product Shortages - update - 19 February 2020 Advisory
17/02/2020 XELJANZ (tofacitinib): Important Safety Information from Pfizer Healthcare Ireland as approved by the HPRA 3rd Party Publications
13/02/2020 HPRA MIMS Article January 2020 3rd Party Publications
13/02/2020 HPRA MIMS Articles December 2019 3rd Party Publications